Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:CGEN NASDAQ:INBX NASDAQ:SPPI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$2.59-2.6%$2.59$1.20▼$6.75$151.26M2.87893,995 shs708,420 shsCGENCompugen$1.48+2.1%$1.62$1.13▼$2.66$129.39M2.61236,550 shs282,242 shsINBXInhibrx Biosciences$21.60-1.5%$17.61$10.80▼$25.29$317.31M0.22145,336 shs58,806 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-2.63%-12.79%-0.38%+45.51%-57.47%CGENCompugen+2.07%-3.27%-14.94%0.00%-16.38%INBXInhibrx Biosciences-1.46%-6.41%+37.23%+77.78%+48.86%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDTXBlack Diamond Therapeutics2.3023 of 5 stars3.51.00.00.03.11.70.6CGENCompugen2.0068 of 5 stars3.54.00.00.02.00.00.0INBXInhibrx Biosciences1.3548 of 5 stars0.01.00.04.60.62.51.3SPPISpectrum Pharmaceuticals0.4352 of 5 stars0.00.00.04.70.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 3.00Buy$12.80394.21% UpsideCGENCompugen 3.00Buy$4.00170.27% UpsideINBXInhibrx Biosciences 2.00HoldN/AN/ASPPISpectrum Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BDTX, INBX, SPPI, and CGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025BDTXBlack Diamond TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform$11.005/15/2025INBXInhibrx BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond TherapeuticsN/AN/AN/AN/A$1.47 per shareN/ACGENCompugen$27.86M4.74N/AN/A$0.62 per share2.39INBXInhibrx Biosciences$200K1,563.84$113.68 per share0.19$9.23 per share2.34SPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics-$69.68M$0.0643.17N/AN/AN/A4.70%3.47%8/5/2025 (Estimated)CGENCompugen-$14.23M-$0.16N/AN/AN/A-51.27%-24.51%-12.19%8/6/2025 (Estimated)INBXInhibrx Biosciences$1.69B$116.750.19N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)SPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/ALatest BDTX, INBX, SPPI, and CGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025INBXInhibrx Biosciences-$2.92N/AN/AN/AN/AN/A8/6/2025Q2 2025CGENCompugen-$0.07N/AN/AN/A$3.95 millionN/A8/5/2025Q2 2025BDTXBlack Diamond Therapeutics-$0.26N/AN/AN/AN/AN/A5/19/2025Q1 2025CGENCompugen-$0.06-$0.08-$0.02-$0.08$3.70 million$2.28 million5/14/2025Q4 2024INBXInhibrx Biosciences-$2.55-$2.80-$0.25-$2.80N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/ACGENCompugenN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A9.249.24CGENCompugenN/A5.095.09INBXInhibrx Biosciences1.045.125.12SPPISpectrum PharmaceuticalsN/A2.712.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%CGENCompugen12.22%INBXInhibrx Biosciences82.46%SPPISpectrum Pharmaceuticals21.67%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics5.97%CGENCompugen9.50%INBXInhibrx Biosciences17.09%SPPISpectrum Pharmaceuticals2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9056.86 million53.47 millionOptionableCGENCompugen7089.24 million80.76 millionOptionableINBXInhibrx Biosciences16614.48 million12.00 millionOptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableBDTX, INBX, SPPI, and CGEN HeadlinesRecent News About These CompaniesFilgotinib Shows Positive Topline Results Across Full Spectrum of Axial Spondyloarthritis in OLINGUITO Phase 3 StudyJuly 28, 2025 | businesswire.comPneumagen Announces Peer-Reviewed Publication of Positive Phase II Study Data Highlighting the Potential of Neumifil, a Novel Broad-Spectrum AntiviralJuly 2, 2025 | globenewswire.comIDMC Provides Positive Recommendation for Bio-Thera Solution's BAT4406F (ADCC-Enhanced Anti-CD20 mAb) in Neuromyelitis Optica Spectrum Disorder Based on Interim Analysis of Pivotal Phase II/III TrialJuly 2, 2025 | prnewswire.comThere is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug CandidateJuly 1, 2025 | accessnewswire.comAOsivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 s releaseJune 5, 2025 | globenewswire.comBroad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of CongoMay 8, 2025 | accessnewswire.comABio-Thera Solutions Publishes Phase I Clinical Study Results for BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum DisordersJanuary 14, 2025 | prnewswire.comNon-Hodgkin’s Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and BarriersNovember 4, 2024 | theglobeandmail.comSpectrum Thin Films, Inc.October 31, 2024 | optics.orgOIndia – Key Considerations For Patenting Nutraceuticals/Dietary Supplements.October 10, 2024 | conventuslaw.comCQylur Awarded SBIR Phase II Contract for a Tactical AI Spectrum Classifier Systems (TASCS)October 2, 2024 | globenewswire.comNanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387August 19, 2024 | proactiveinvestors.comGPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to TaxanesAugust 19, 2024 | br.advfn.comGlobal AL Amyloidosis Therapeutics Market Set for Remarkable Growth, Projected to Reach USD 4.56 Billion by 2033July 31, 2024 | fmiblog.comFCompany History - Paam Drugs and PharmaceuticalsJuly 19, 2024 | moneycontrol.comSTALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in BiomedicinesJune 27, 2024 | globenewswire.comOsivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033June 25, 2024 | businesswire.comPneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 ConferenceMay 23, 2024 | globenewswire.comPneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024May 2, 2024 | globenewswire.comSpectrum Pharmaceuticals gets grant for crystalline form of quinazoline compound and hydrochloride saltsApril 24, 2024 | pharmaceutical-technology.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBDTX, INBX, SPPI, and CGEN Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$2.59 -0.07 (-2.63%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.62 +0.03 (+1.16%) As of 08/1/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Compugen NASDAQ:CGEN$1.48 +0.03 (+2.07%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.50 +0.02 (+1.35%) As of 08/1/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Inhibrx Biosciences NASDAQ:INBX$21.60 -0.32 (-1.46%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$21.64 +0.04 (+0.19%) As of 08/1/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Spectrum Pharmaceuticals NASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
